We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

BioLineRx Announces Publication of BL-5010 Phase 1/2 Trial Results

News   Jun 04, 2015

 
BioLineRx Announces Publication of BL-5010 Phase 1/2 Trial Results
 
 
Advertisement
 

RELATED ARTICLES

BCG Vaccine Does Not Protect Against COVID-19, Data Suggests

News

Using information from the Swedish public health agency, researchers determined that BCG vaccination during infancy actually does not protect against the SARS-CoV-2 virus.

READ MORE

KRAS Inhibitor Sotorasib Achieves Durable Clinical Benefit in Early Trial

News

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefit.

READ MORE

Adding Abemaciclib to Hormonal Therapy Reduces Risk of Cancer Recurrence in Patients With High-Risk Early HR+ HER2- Early Breast Cancer

News

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to trial results.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE